MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $116.30 million. The enterprise value is $47.32 million.
Important Dates
The next estimated earnings date is Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 63.21 million shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | 63.21M |
| Shares Outstanding | 63.21M |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 2.39% |
| Owned by Institutions (%) | 62.24% |
| Float | 52.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.70 |
| Forward PS | 2.17 |
| PB Ratio | 2.49 |
| P/TBV Ratio | 2.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.26, with a Debt / Equity ratio of 2.31.
| Current Ratio | 5.26 |
| Quick Ratio | 4.85 |
| Debt / Equity | 2.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -89.69 |
Financial Efficiency
Return on equity (ROE) is -69.71% and return on invested capital (ROIC) is -39.65%.
| Return on Equity (ROE) | -69.71% |
| Return on Assets (ROA) | -21.84% |
| Return on Invested Capital (ROIC) | -39.65% |
| Return on Capital Employed (ROCE) | -37.80% |
| Revenue Per Employee | $485,323 |
| Profits Per Employee | -$106,742 |
| Employee Count | 341 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 34.95 |
Taxes
In the past 12 months, MacroGenics has paid $1.05 million in taxes.
| Income Tax | 1.05M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.30% in the last 52 weeks. The beta is 1.61, so MacroGenics's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -53.30% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.84 |
| Relative Strength Index (RSI) | 55.17 |
| Average Volume (20 Days) | 733,906 |
Short Selling Information
The latest short interest is 3.56 million, so 5.63% of the outstanding shares have been sold short.
| Short Interest | 3.56M |
| Short Previous Month | 3.54M |
| Short % of Shares Out | 5.63% |
| Short % of Float | 6.77% |
| Short Ratio (days to cover) | 3.90 |
Income Statement
In the last 12 months, MacroGenics had revenue of $165.50 million and -$36.40 million in losses. Loss per share was -$0.58.
| Revenue | 165.50M |
| Gross Profit | -16.09M |
| Operating Income | -78.03M |
| Pretax Income | -35.35M |
| Net Income | -36.40M |
| EBITDA | -70.46M |
| EBIT | -78.03M |
| Loss Per Share | -$0.58 |
Full Income StatementBalance Sheet
The company has $176.49 million in cash and $107.51 million in debt, giving a net cash position of $68.98 million or $1.09 per share.
| Cash & Cash Equivalents | 176.49M |
| Total Debt | 107.51M |
| Net Cash | 68.98M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 46.62M |
| Book Value Per Share | 0.74 |
| Working Capital | 165.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$72.12 million and capital expenditures -$2.46 million, giving a free cash flow of -$74.58 million.
| Operating Cash Flow | -72.12M |
| Capital Expenditures | -2.46M |
| Free Cash Flow | -74.58M |
| FCF Per Share | -$1.18 |
Full Cash Flow StatementMargins
Gross margin is -9.72%, with operating and profit margins of -47.15% and -21.99%.
| Gross Margin | -9.72% |
| Operating Margin | -47.15% |
| Pretax Margin | -21.36% |
| Profit Margin | -21.99% |
| EBITDA Margin | -42.58% |
| EBIT Margin | -47.15% |
| FCF Margin | n/a |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | -1.07% |
| Earnings Yield | -31.30% |
| FCF Yield | -64.12% |
Analyst Forecast
The average price target for MacroGenics is $3.20, which is 73.91% higher than the current price. The consensus rating is "Hold".
| Price Target | $3.20 |
| Price Target Difference | 73.91% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -0.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -6.13 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.13 |
| Piotroski F-Score | 3 |
